Diplomat Pharmacy (DPLO) Tops Q1 EPS by 1c; Boosts FY15 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/7/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Trump held multiple undisclosed calls with Fed Chair Warsh, reports say
- Citi says buy the pullback in memory stocks as upcycle is still in early innings
- Stocks close lower as investors eye Mideast talks, earnings
- The Trade Desk Inc. (TTD) Tops Q2 EPS by 16c, Misses on Revenue; Offers Weak Q3 Revenue Guidance
- Apollo to acquire easyJet for £5.7B in cash deal
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Leerink Partners Maintains OP Following Diplomat Pharmacy (DPLO) Q1
May 12, 2015 11:14 AM EDTLeerink Partners maintains an Outperform rating on Diplomat Pharmacy (NYSE: DPLO), and raised the price target to $40.00 (from $36.00), following the release on the 1Q15 results. Diplomat reported an adjusted EPS of $0.09 (+57% y/y), which was $0.01 ahead of Leerink estimates and consensus. Total revenue of $625M increased +34% y/y. Revenue was slightly ahead of Leerink estimate
but below consensus.
Leerink analyst, David Larsen, commented on the... More
Diplomat Pharmacy (DPLO) PT Raised to $40 at Credit Suisse
May 12, 2015 8:03 AM EDTCredit Suisse analyst G. Santangelo raised its price target on Outperform-rated Diplomat Pharmacy (NYSE: DPLO) to $40.00 (from $37.00) following Q1 'beat and raise'.
For an analyst ratings summary and ratings history on Diplomat Pharmacy... More
